Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network.

BACKGROUND: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest. METHODS: The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021. RESULTS: Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization. CONCLUSIONS: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.

Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases.

Introduction: The COVID-19 pandemic has challenged health care across the world, not just by the severity of the disease and the high mortality rate but also by the consequences on the management of the patients with chronic diseases.Areas covered: This review summarizes the most up-to-date published data regarding the impact of COVID-19 on the management and outcomes of patients with chronic noninfectious respiratory illnesses including obstructive sleep apnea, asthma, chronic obstructive pulmonary disease, bronchiectasis, interstitial and pulmonary vascular diseases, and lung cancer.Expert opinion: Most of chronic respiratory diseases (except asthma and cystic fibrosis) are associated with more severe COVID-19 and poor outcomes but the mechanisms involved are not yet identified. The therapeutic management of the patients with chronic respiratory diseases and COVID-19 is similar to the other patients but the post-recovery course could be worse in this population and followed by the development of pulmonary fibrosis, bronchiectasis, and pulmonary hypertension. The pandemic highly impacted our usual medical activities by limiting the access to several diagnosis procedures, the necessity to develop new methods for the monitoring of the disease and adapt the therapeutic strategies. The long-term consequences of all these changes are still unknown.

Early indicators and risk factors associated with mental health problems during COVID-19 quarantine: Is there a relationship with the number of confirmed cases and deaths?

BACKGROUND: On March 20 2020, the Argentine Ministry of Health enforced a mandatory quarantine throughout the country in response to the COVID-19 pandemic. AIMS: The object of this study is to determine the initial impact on mental health of Argentine population, by measuring the prevalence of anxiety, depression, insomnia, and self-perceived stress and by determining the associated risk factors, and to analyze that impact in relation to the number of confirmed cases and deaths. METHOD: A cross-sectional survey was conducted through a digital questionnaire, which was completed by 1,985 respondents between March 29 and April 12. The prevalence of anxiety, depression, stress and insomnia was measured with the Generalized Anxiety Disorder-7 Scale (GAD-7), the 9-Item Patients Health Questionnaire (PHQ-9); the Perceived Stress Scale (PSS-10) and the Pittsburgh Sleep Quality Index (PSQI), respectively. RESULTS: The 62.4% of the surveyed population reported signs of psychological distress. It was found that being a woman, being 18 to 27 years old, living with family members or a partner, smoking, and having a poor sleep quality were the significant risk factors. CONCLUSION: Despite the low number of COVID-19 confirmed cases and deaths at that time, a strong impact on mental health indicators was revealed. The authors of this study recommend the monitoring of the population at risk over time and early interventions in order to avoid long-lasting mental health problems.